Mehabe score: 5 G Factor: 6 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 6 and Piotski score of 8.
Description
Emmessar Biotech & Nutrition is a global healthcare company that manufactures and markets healthcare & nutritional products.(Source : Company web-site)Site:524768Main Symbol:EMMESSA
Stock trades at 55.6, above its 50dma 40.16. It also trades above its 200dma 27.02. The stock remains bullish on techicals
The 52 week high is at 54.50 and the 52week low is at 12.09
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has a good return on equity (ROE) track record: 3 Years ROE 26.14%
Weakness
– Though the company is reporting repeated profits, it is not paying out dividend
-Earnings include an other income of Rs.1.47 Cr.
-Debtor days have increased from 55.97 to 141.51 days.
Competition
– The industry trades at a mean P/E of 30.6x. Pidilite Inds. trades at the industry’s max P/E of 103.19x. 524768 trades at a P/E of 19.2x
– Industry’s mean G-Factor is 4.1 while the mean Piotski score is 8.0. 524768 has a G-Factor of 6 and Piotski scoreof 8.
– Average 1 month return for industry is 19.0%. The max 1- month return was given by Gujarat Fluoroch: a return of 67.55 %
Quarterly Results
Sales for period ended Jun 2021 is Rs 0.02 cr compared to Rs 0.29 cr for period ended Jun 2020, a fall of 93.1%
Company reported negative operating profit of Rs -0.28 cr for period ended Jun 2021. For same period last year, operating profit was -0.15
The EPS for Jun 2021 was Rs 0.18 compared to Rs 1.04 for previous quarter ended Mar 2021 and Rs 0.06 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 6.72 cr for period ended TTM vis-vis sales of Rs 6.99 cr for the period ended Mar 2021, a fall of 4.0%. The 3 year sales cagr stood at 120.1%.
Operating margins shrank to 10.86% for period ended TTM vis-vis 12.02% for period ended Mar 2021, contraction of 116.0 bps.
Net Profit reported at Rs 1.51 cr for period ended TTM vis-vis sales of Rs 1.45 cr for the period ended Mar 2021, rising 4.0%.
Company recorded a healthy Net Profit CAGR of 41.8% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The stock has given a return of 338% on a 1 Year basis vis-vis a return of 32% over the last 3 Years. – The compounded sales growth on a TTM bassis is 106% vis-vis a compounded sales growth of 77% over the last 3 Years. – The compounded profit growth on a TTM basis is 51% vis-vis a compounded profit growth of 17% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Jun 2021 public holding stood at 41.31% vis-vis 41.31% for Mar 2021
Conclusion
– is almost debt free.
– has a good return on equity (ROE) track record: 3 Years ROE 26.14% – Though the company is reporting repeated profits, it is not paying out dividend
-Earnings include an other income of Rs.1.47 Cr.
-Debtor days have increased from 55.97 to 141.51 days.
